Treating Iron Deficiency Anemia in Patients With Inflammatory Bowl Disorder

By October 19, 2017

Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.

Recall of Erythropoiesis-Stimulating Agent Expanded

By September 26, 2017

The recall is due to the finding of glass flakes (lamellae) observed in 2 additional Lots during a routine inspection.

Aplastic Anemia Outcomes Examined for Anti-Thymoglobulin-Based IST

September 07, 2017

The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.

ESA Agent Recalled Due to Presence of Particulate in Vials

By August 22, 2017

Healthcare professionals are urged to following the package insert instructions regarding careful inspection of vials.

Eculizumab Linked to High Risk of Meningococcal Disease, Despite Vaccination

By July 10, 2017

In vitro data have shown that eculizumab impairs meningococcal killing in whole blood despite patients being vaccinated against the appropriate serogroup. The current vaccines against meningococcal disease only target serogroup-specific proteins and do not provide protection against nongroupable N. meningitidis.

Breckenridge Approved for Generic Vidaza

By June 29, 2017

Vidaza is indicated as treatment for myelodysplastic syndrome (MDS), specifically refractory anemias and chronic myelomonocytic leukemia; it can be given either subcutaneously (SC) or intravenously (IV).

Ferrous Sulfate vs. Iron Polysaccharide in Iron-Deficient Anemic Infants

June 14, 2017

The researchers found that the mean hemoglobin increased from 7.9 to 11.9 g/dL in the ferrous sulfate group, compared with 7.7 to 11.1 g/dL in the iron polysaccharide complex group (greater difference of 1.0 g/dL with ferrous sulfate).

First ESA Biosimilar Gets FDA Advisory Committee Nod

By May 26, 2017

The FDA will consider the Committee's recommendation before acting on the biologics license application (BLA) for the epoetin alfa biosimilar.

FDA Committee Votes in Favor of Endari for Sickle Cell Disease

By May 25, 2017

An efficacy study of L-glutamine (Study 09-01) showed that the treatment resulted in a lower frequency of sickle cell painful crises, longer time to first and second crisis compared to placebo.

FDA: Prescribing Change for ESAs

By April 13, 2017

The decision was made based on data which showed that clinicians demonstrated acceptable knowledge of the product risks.

Stem Cell Transplant Cures First Adult Patient of Rare Blood Disorder

By March 21, 2017

The patient underwent a non-myeloablative (NMA) peripheral blood stem cell transplant from a 10/10 HLA Ag matched, ABO incompatible unrelated donor.

Warm Autoimmune Hemolytic Anemia Occurs After Babesiosis

March 10, 2017

The researchers documented warm autoimmune hemolytic anemia following babesiosis in patients with no history of autimmunity, they said there was no alternative explanation for clinical hemolysis.

ACOG Updates Recommendations on Carrier Screening

February 27, 2017

Ethnic-specific, panethnic, and expanded carrier screening are all acceptable screening strategies.

Testosterone Trials Show Short-Term Benefits but CV Risk Still Unclear

February 22, 2017

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Thrombotic Microangiopathy Cases Prompt Update to Antifungal Drug Labeling

By January 25, 2017

The labeling for Lamisil (terbinafine hydrochloride) Tablets and Oral Granules has been updated to include a new warning regarding the risk of thrombotic microangiopathy.

Iron Deficiency Anemia Linked to Hearing Loss in Adults

January 03, 2017

After adjustment for sex, adults with IDA have increased odds of SNHL, combined hearing loss

ASH: P-Selection Antibody Significantly Lowers Sickle Cell Pain Crises

By December 06, 2016

High-dose crizanlizumab treatment is associated with a significantly lower rate of sickle cell-related pain crises than placebo, according to a new study

FDA to Review Novel Sickle Cell Disease Therapy

By November 09, 2016

Emmaus Life Sciences has announced that the Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for its orally administered pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell disease.

Fatal Anaphylaxis Cases Reported with IV Iron Products

September 12, 2016

Seventy-nine cases of anaphylactic reactions linked to ferumoxytol, of which 18 were fatal

FDA to Review Oral Pharmaceutical Grade L-glutamine for Sickle Cell Disease

By September 08, 2016

Emmaus Life Sciences announced its submission, with request for Priority Review, to the Food and Drug Administration (FDA) a New Drug Application (NDA) for an orally administered pharmaceutical grade L-glutamine (PGLG) for the treatment of sickle cell disease in adults and pediatric patients.

Study Sheds Light on Anemia and Mortality Following Stroke

August 18, 2016

Anemia may increase mortality risk for older stroke patients, according to research published online in the Journal of the American Heart Association.

Risk of Death May Not Significantly Increase With Sickle Cell Trait

August 04, 2016

Sickle cell trait is not associated with a higher risk of death than absence of the trait, but it is associated with a significantly increased risk of exertional rhabdomyolysis, according to a study published in the August 4 issue of the New England Journal of Medicine.

Ferumoxytol Effective in Iron Deficiency Anemia Patients With Comorbid GI Disorders

By July 29, 2016

Treatment with ferumoxytol for patients with iron deficiency anemia (IDA) and comorbid gastrointestinal disorders was found to be efficacious and generally well-tolerated in an analysis of a Phase 3 trial.

Hydroxyurea May Improve Lung Function in Children With Sickle Cell Disease

By May 18, 2016

Children with sickle cell disease had improved lung function after treatment with hydroxyurea, according to a study presented at the American Thoracic Society (ATS) 2016 International Conference.

Preventing Anemia After Orthopedic Surgery: The Role of Iron, ESA Pharmacotherapy

By May 09, 2016

The use of intravenous (IV) or oral iron with or without an erythropoiesis-stimulating agent (ESA) may help prevent post-operative anemia and reduce blood transfusion without significantly raising the risk of adverse events, study authors reported in a study published in Annals of Pharmacotherapy.

Triferic Powder Packets Approved for Iron Replacement in Hemodialysis Patients

By April 27, 2016

Rockwell Medical announced that the Food and Drug Administration (FDA) has approved Triferic (ferric pyrophosphate citrate) powder packet for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (CKD).

Can Testosterone Tx Reduce Anemia in Hypogonadal Men?

April 18, 2016

Decreased prevalence of anemia and components of metabolic syndrome after 54 weeks of tx

Predictors of Survival Examined in RARS-T

February 22, 2016

New mutations have been identified with next-generation sequencing (NGS) in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T), which are prognostic for survival, according to a study published online in the American Journal of Hematology.

Do ESAs Improve Quality of Life in Anemia of CKD?

February 16, 2016

Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets

Positive Data from Aranesp MDS Study Announced

By February 16, 2016

Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp (darbepoetin alfa) in anemic patients with low and intermediate-1 risk myelodysplastic syndrome (MDS).